Vertex Pharmaceuticals Inc (VRTX)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 4,379,800 | 4,232,400 | 2,730,400 | 3,116,900 | 1,394,900 |
| Revenue | US$ in thousands | 9,803,200 | 8,863,500 | 7,499,400 | 6,135,450 | 4,105,510 |
| Pretax margin | 44.68% | 47.75% | 36.41% | 50.80% | 33.98% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $4,379,800K ÷ $9,803,200K
= 44.68%
The pretax margin for Vertex Pharmaceuticals, Inc. has shown fluctuations over the past five years. In 2023, the pretax margin decreased to 44.38% from 47.39% in 2022 but remained higher compared to 2021 when it was 36.05%. The highest pretax margin was recorded in 2020 at 50.22%, showing a strong performance in that year. In contrast, the pretax margin in 2019 was 33.51%, indicating a lower profitability level compared to the other years in consideration. Overall, Vertex Pharmaceuticals, Inc. has demonstrated varying levels of profitability before taxes over the analyzed period. Further analysis would be needed to understand the specific factors driving these fluctuations in the pretax margin.
Peer comparison
Dec 31, 2023